Healthcare Industry News: Allograft
News Release - July 7, 2006
Clearant Sterile Bone Implants Used for First Time in Successful Spinal Surgery at UCLA
Company Achieves Significant Milestone in Direct Distribution ProgramLOS ANGELES--(HSMN NewsFeed)--July 7, 2006--Clearant, Inc. (OTCBB:CLRI ) today announced that two Clearant Sterile Implants were used in a successful two-level cervical fusion surgery done last week at the University of California, Los Angeles. This represents the first use of sterile bone Allograft implants supplied through Clearant's new direct distribution program. The procedure was performed by Jeffrey C. Wang, M.D., Chief, Orthopedic Spine Service, and Associate Professor of Orthopedics and Neurosurgery at the UCLA School of Medicine.
"This successful procedure in one of the country's leading medical institutions demonstrates the progress of our new growth initiative to distribute directly to hospitals and surgeons," said Clearant Chief Executive Officer Alain Delongchamp. "We are very pleased that highly respected surgeons such as Dr. Wang are choosing Clearant Sterile Implants based on safety and quality. The support of these opinion-leading surgeons is key to educating the larger orthopedic surgeon community about the benefits of Clearant Process Sterile Implants."
In June, Clearant announced that in order to meet the rising demand for sterile tissue implants, it would become a direct distributor of Clearant Process® treated bone tissue. The Company now has six territory representatives focused strictly on this effort. Currently, the top fifteen markets in the U.S. represent in excess of $200 million in bone implant sales. The top 30-50 surgeons in these markets perform approximately 80% of the procedures, allowing the Company to employ a highly targeted marketing effort.
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.
Source: Clearant
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!